Previous 10 | Next 10 |
Investors looking for biotech stocks to buy will notice lots of buzz around Amgen (NASDAQ: AMGN) and Mirati Therapeutics (NASDAQ: MRTX) lately. Both companies are developing similar new cancer treatments that could go on to generate billions in annual sales, and there are pl...
Mirati Therapeutics (MRTX) announces public offering of $700M of its common stock and a selling stockholder intends to offer 375k shares in the offering.Price and number of shares are yet to be determined. For further details see: Mirati Therapeutics launches equity offering of $70...
Shares of Mirati Therapeutics (NASDAQ: MRTX) were jumping 12.6% as of 11:17 a.m. EDT on Monday. The nice gain came after the company announced positive preliminary data on Sunday from phase 1/2 clinical studies of experimental drug adagrasib in treating advanced non-small cell lung ...
Gainers: Lianluo Smart (LLIT) +30%, Galera Therapeutics (GRTX) +18%, Selecta Biosciences (SELB) +16%, Mirati Therapeutics (MRTX) +14%, GeoVax Labs (GOVX) +14%.Losers: BioSig Technologies (BSGM) -40%, Aileron Therapeutics (ALRN) ...
Mirati Therapeutics (MRTX) reports preliminary results from its mutant KRAS selective inhibitor programs. The results included updated clinical data of adagrasib (MRTX849), a KRAS G12C inhibitor, presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutics and initial ...
Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data - 45% confirmed ORR and 96% DCR across Phase 1/1b and Phase 2 monotherapy cohorts in patients ...
Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA) - Updated adagrasib (MRTX849) clinical data in non-small cell lung cancer (NSCLC) patients will be featured in a plenary session at ENA...
Mirati achieves positive results in phase 2 open-label study using sitravatinib to treat patients with metastatic or advanced urothelial carcinoma who have the KRAS mutation. Sitravatinib is a multi-kinase drug that targets RTK pathway which includes TAM family, VEGFR2 and KIT; This d...
Mirati Therapeutics (NASDAQ: MRTX ) has announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO) in patients with advanced or metastatic urothelial carcinoma. Data were presented at the European Society for Medical Oncolog...
SAN DIEGO , Sept. 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO ® ) in patients with ...
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
2023-12-18 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...